Actively Recruiting
Retinal Hyperspectral Imaging in Neurodegenerative Diseases
Led by Center for Eye Research Australia · Updated on 2026-04-22
930
Participants Needed
1
Research Sites
376 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Hyperspectral retinal imaging is a non-invasive imaging modality in which a series of images of the retina are captured using light of different wavelengths. The resulting "hypercube" of data provides a wealth of information about the retinal structure. Our group has developed evidence supporting a role for this technology in the detection of retinal amyloid beta in Alzheimer's disease. We are undertaking further studies to establish the role of this method in the assessment of people with dementia, or those at risk of Alzheimer's disease. In addition, we wish to test whether the approach may have value in other forms of dementia or neurodegenerative disease such as Parkinson's disease, Lewy-Body dementia or vascular dementia.
CONDITIONS
Official Title
Retinal Hyperspectral Imaging in Neurodegenerative Diseases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged over 30 years
- Diagnosed with dementia or a neurodegenerative disease such as Alzheimer's disease, Parkinson's disease, Lewy body dementia, Niemann-Pick type 2, or vascular dementia; age-matched and sex-matched controls also accepted
- Except for Parkinson's and Lewy body disease, must have prior diagnostic confirmation by genetic tests, blood biomarkers, brain amyloid beta PET scan, or cerebrospinal fluid tests
- Best corrected visual acuity of at least 6/60 in both eyes
- No major eye problems such as advanced age-related macular degeneration, advanced glaucoma, or greater than moderate non-proliferative diabetic retinopathy
- Willing to participate and attend the Centre for Eye Research Australia
- Must be accompanied by a friend or family member
You will not qualify if you...
- Unable to provide informed consent
- Ocular conditions that prevent adequate retinal imaging such as dense cataract, severe corneal opacity, or vitreous haemorrhage
- Known contraindication to pharmacological pupil dilation
- Any condition that would compromise participant safety or image quality, as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Centre for Eye Research Australia
Melbourne, Victoria, Australia, 3002
Actively Recruiting
Research Team
D
Darvy Dang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here